RESEARCH PEPTIDE FUNDAMENTALS
Compare the Four Peptide Classes
BPC-157, Ipamorelin, Retatrutide and Thymosin Alpha-1 — lined up by class, mechanism, human evidence and regulatory status.
The short version
Four research peptides, four distinct signaling strategies. BPC-157 is a cytoprotective peptide working through angiogenesis at the tissue level. Ipamorelin is a secretagogue that triggers pulsatile growth hormone release from the pituitary. Retatrutide is an investigational incretin triple-agonist managing appetite, glucose metabolism and energy expenditure via three simultaneous receptor targets. Thymosin Alpha-1 is an immune modulator shaping T-cell education and dendritic-cell maturation at the innate-adaptive interface.
They share almost no mechanism. They share a class label (research peptides) and a regulatory reality (none is an FDA-approved drug in general use). The table and notes below make those distinctions concrete.
Head-to-head comparison
| Peptide | Class | Primary mechanism | What it is primarily studied for | Best human evidence | Regulatory status | WADA status |
|---|---|---|---|---|---|---|
| BPC-157 | Cytoprotective | VEGFR2 angiogenesis + nitric-oxide signaling | Tissue repair (tendon, gut, muscle) in animal models | First-in-human safety pilot (n=2); narrative reviews only [1][2] | Not approved anywhere; 503A compounding ineligible (FDA) | Prohibited (S0, all times) |
| Ipamorelin | GH Secretagogue | GHS-R1a agonism → pituitary GH pulse | GH axis stimulation, preclinical bone and body composition | Human PK/PD study (n=8); Phase 2 RCT failed primary endpoint (n=114) [8][9] | Never approved; removed from 503A Category 2 (2024) | Prohibited (S2, all times) |
| Retatrutide | Incretin Triple-Agonist | GLP-1R + GIPR + GCGR simultaneous agonism | Obesity, type 2 diabetes, metabolic liver disease | Phase 2 trials (338–338 adults, 48 wk obesity; 281 adults, 36 wk T2D) [16][17] | Investigational; Phase 3 ongoing; not approved | Not specifically prohibited (verify current WADA list) |
| Thymosin Alpha-1 | Immune Modulator | TLR2/TLR9 → dendritic-cell maturation + Th1 polarization | Chronic hepatitis, sepsis, cancer immunotherapy adjuvant | Multiple RCTs including Phase 3 sepsis trial (n=1,106; null) [18][22] | Approved as drug in 35+ countries; not FDA-approved in the US | Not specifically prohibited (verify current WADA list) |
What the comparison reveals
Evidence maturity varies enormously. Thymosin Alpha-1 has the deepest clinical record — decades of trials across hepatitis, sepsis and cancer contexts — yet its most recent, most rigorous test (a 2025 Phase 3 sepsis RCT) was null [18]. Retatrutide has the youngest and most prospective evidence: large Phase 2 RCTs with striking weight-loss numbers, but Phase 3 still ongoing [13]. Ipamorelin has one failed Phase 2 trial and one human PK study from 1999 as its entire controlled human dataset [8][9]. BPC-157 has the preclinical depth and the shallowest human file: two safety-pilot subjects as of the most recent review [1][2].
Mechanism does not predict regulatory approval. All four have coherent, published mechanistic rationales. None is an approved FDA drug for general use. Mechanism and preclinical promise do not translate automatically into approval-grade safety and efficacy — the histories of ipamorelin and thymosin alpha-1, each of which has had controlled human trials, underscore this point [8][18].
WADA status matters for athletes. BPC-157 and Ipamorelin are both prohibited in sport at all times. Athletes should verify Retatrutide and Thymosin Alpha-1 status against the current WADA Prohibited List before assuming they are permissible.
Gray-market quality risk applies to all four. Research-grade material purchased outside a clinical trial context has no guaranteed identity, purity or sterility for any of these compounds, regardless of how well-established the molecule's pharmacology is in the formal literature.